Table 3.
Clinical biomarkers and CMR parameters at baseline and follow-up among IIM patients with CMR follow-up
| Baseline (n = 28) | Follow-up (n = 28) | P* value | |
|---|---|---|---|
| Biomarker | |||
| Hct | 0.40 ± 0.05 | 0.43 ± 0.04 | 0.005 |
| CRP (mg/L) | 5.7 (2.8–17.9) | 2.2 (1.8–4.1) | 0.024 |
| ESR (mm/h) | 26 (23–47) | 22 (5–33) | 0.064 |
| CK (U/L) | 479 (83–1060) | 106 (75–148) | 0.038 |
| CK-MB (ng/mL) | 24.7 (7.1–74.6) | 2.5 (1.0–4.8) | < 0.001 |
| cTnT (g/L) | 102 (60–480) | 17 (10–67) | < 0.001 |
| BNP (pg/mL) | 235 (72–1184) | 50 (26–109) | 0.007 |
| Structural and function | |||
| LVEDVi, ml3/m2 | 83.7 ± 19.4 | 82.3 ± 18.0 | 0.703 |
| LVESVi, ml3/m2 | 34.0 ± 15.3 | 34.3 ± 13.8 | 0.549 |
| LVmassi, g/m2 | 51.2 ± 12.5 | 45.2 ± 10.2 | 0.011 |
| LVEF, % | 59.4 ± 8.7 | 60.5 ± 10.5 | 0.395 |
| RVEDVi, ml3/m2 | 81.8 ± 16.2 | 79.8 ± 11.6 | 0.279 |
| RVESVi, ml3/m2 | 39.3 ± 11.8 | 37.4 ± 8.0 | 0.073 |
| RVEF, % | 53.2 ± 6.2 | 55.2 ± 6.8 | 0.492 |
| Myocardial tissue characteristics | |||
| T2w ratio | 1.3 ± 0.5 | 1.3 ± 0.4 | 0.621 |
| LGE presence, n(%) | 7 (25%) | 7 (25%) | 1 |
| LGE extent, % | 11.8 ± 2.9 | 8.1 ± 2.0 | 0.239 |
| Native T1-myo, ms | 1289 ± 53 | 1262 ± 59 | 0.013 |
| T2 mapping-myo, ms | 44.4 ± 4.0 | 41.8 ± 4.2 | 0.001 |
| ECV-myo, % | 30.7 ± 4.1 | 27.6 ± 4.4 | 0.001 |
| Skeletal tissue characteristics | |||
| Native T1-sk, ms | 1268 ± 103 | 1154 ± 73 | < 0.001 |
| T2 mapping-sk, ms | 34.5 ± 3.5 | 29.7 ± 2.8 | < 0.001 |
| ECV-sk, % | 29.2 ± 11.1 | 21.9 ± 11.2 | 0.011 |
Abbreviations: Hct hematocrit, CRP C-reactive protein, ESR erythrocyte sedimentation rate, CK creatine kinase, CK-MB creatine kinase-MB, TnT troponin T, NT-proBNP N-terminal pro b-type natriuretic peptide, LVEDVi left ventricular end-diastolic volume index, LVESVi left ventricular end-systolic volume index, LVmassi left ventricular mass index, LVEF left ventricular ejection fraction, RVEDVi right ventricular end-diastolic volume index, RVESVi right ventricular end-systolic volume index, RVEF right ventricular ejection fraction, T2W T2-weighted ratio, LGE late gadolinium enhancement, ECV extracellular volume fraction
Values in bold indicate P values < 0.05
P* value for comparison between baseline and follow-up characteristics among IIM patients